ORIC Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$140.4MTTM through 30 Jun 2026
Free Cash Flow -$112.3MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-41.3%ROE
-34.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio13.19x
Net Debt-$392.3Mnet cash position
Cash & Equivalents$37.5M
Quality Metrics
Altman Z-Score32.65
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
Diluted EPS-$1.30TTMFY2025: $-1.47
Dividend
No dividend
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.